Episodic ataxia

(Redirected from Episodic Ataxia)
Jump to navigation Jump to search

WikiDoc Resources for Episodic ataxia

Articles

Most recent articles on Episodic ataxia

Most cited articles on Episodic ataxia

Review articles on Episodic ataxia

Articles on Episodic ataxia in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Episodic ataxia

Images of Episodic ataxia

Photos of Episodic ataxia

Podcasts & MP3s on Episodic ataxia

Videos on Episodic ataxia

Evidence Based Medicine

Cochrane Collaboration on Episodic ataxia

Bandolier on Episodic ataxia

TRIP on Episodic ataxia

Clinical Trials

Ongoing Trials on Episodic ataxia at Clinical Trials.gov

Trial results on Episodic ataxia

Clinical Trials on Episodic ataxia at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Episodic ataxia

NICE Guidance on Episodic ataxia

NHS PRODIGY Guidance

FDA on Episodic ataxia

CDC on Episodic ataxia

Books

Books on Episodic ataxia

News

Episodic ataxia in the news

Be alerted to news on Episodic ataxia

News trends on Episodic ataxia

Commentary

Blogs on Episodic ataxia

Definitions

Definitions of Episodic ataxia

Patient Resources / Community

Patient resources on Episodic ataxia

Discussion groups on Episodic ataxia

Patient Handouts on Episodic ataxia

Directions to Hospitals Treating Episodic ataxia

Risk calculators and risk factors for Episodic ataxia

Healthcare Provider Resources

Symptoms of Episodic ataxia

Causes & Risk Factors for Episodic ataxia

Diagnostic studies for Episodic ataxia

Treatment of Episodic ataxia

Continuing Medical Education (CME)

CME Programs on Episodic ataxia

International

Episodic ataxia en Espanol

Episodic ataxia en Francais

Business

Episodic ataxia in the Marketplace

Patents on Episodic ataxia

Experimental / Informatics

List of terms related to Episodic ataxia

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Episodic ataxia (EA) is an autosomal dominant disorder characterized by sporadic bouts of ataxia (severe discoordination) with or without myokymia (continuous muscle movement). Ataxia can be provoked by stress, startle, or heavy exertion such as exercise. Symptoms can first appear in infancy. There are at least 6 loci for EA, of which 4 are known genes. Some patients with EA also have migraine or progressive cerebellar degenerative disorders, symptomatic of either familial hemiplegic migraine or spinocerebellar ataxia. Some patients respond to acetazolamide though others do not.

Signs/Symptoms

Typically, episodic ataxia presents as bouts of ataxia induced by startle, stress, or exertion. Some patients also have continuous tremors of various motor groups, known as myokymia. Other patients have nystagmus, vertigo, tinnitus, diplopia or seizures.

Cause

The various symptoms of EA are caused by dysfunction of differing areas. Ataxia, the most common symptom, is due to misfiring of Purkinje cells in the cerebellum. This is either due to direct malfunction of these cells, such as in EA2, or improper regulation of these cells, such as in EA1. Seizures are likely due to altered firing of hippocampal neurons (KCNA1 null mice have seizures for this reason).

Pathophysiology

EA1: KCNA1

Figure 1. Schematic structure of KV1.1 with the episodic ataxia type 1 mutations noted in red.

Type 1 episodic ataxia (EA1) is characterized by attacks of generalized ataxia induced by emotion or stress, with myokymia both during and between attacks. This disorder is also known as episodic ataxia with myokymia (EAM), hereditary paroxysmal ataxia with neuromyotonia and Isaacs-Mertens syndrome. Onset of EA1 occurs during early childhood to adolescence and persists throughout the patient's life. Attacks last from seconds to minutes. Mutations of the gene KCNA1, which encodes the voltage-gated potassium channel KV1.1, are responsible for this subtype of episodic ataxia. KV1.1 is expressed heavily in basket cells and interneurons that form GABAergic synapses on Purkinje cells. The channels aid in the repolarization phase of action potentials, thus affecting inhibitory input into Purkinje cells and, thereby, all motor output from the cerebellum. There are currently 17 KV1.1 mutations associated with EA1, Table 1 and Figure 1. 15 of these mutations have been at least partly characterized in cell culture based electrophysiological assays wherein 14 of these 15 mutations have demonstrated drastic alterations in channel function. As described in Table 1, most of the known EA1 associated mutations result in a drastic decrease in the amount of current through KV1.1 channels. Furthermore, these channels tend to activate at more positive potentials and slower rates, demonstrated by positive shifts in their V½ values and slower τ activation time constants, respectively. Some of these mutations, moreover, produce channels that deactivate at faster rates (deactivation τ), which would also result in decreased current through these channels. While these biophysical changes in channel properties likely underlie some of the decrease in current observed in experiments, many mutations also seem to result in misfolded or otherwise mistrafficked channels, which is likely to be the major cause of dysfunction and disease pathogenesis. It is assumed, though not yet proven, that decrease in KV1.1 mediated current leads to prolonged action potentials in interneurons and basket cells. As these cells are important in the regulation of Purkinje cell activity, it is likely that this results increased and aberrant inhibitory input into Purkinje cells and, thus, disrupted Purkinje cell firing and cerebellum output.

Table 1. Mutations in KCNA1 related to episodic ataxia type-1
Mutation Position Current amplitude
(% wild-type) 		Activation Deactivation (τ) Other References
V½ τ
V174F S1 7.6% 25mV positive Unchanged Unchanged [1],[2],[3],[4]
I177N S1 5.9% 60mV positive Slower Faster Shorter mean open time and smaller single channel conductance [5],[6]
F184C S1 15.1% 24mV positive Slower Slower Fewer channels at membrane [2],[3],[4],[7]
T226A S2 5% 15mV positive Slower Slower [5],[8]
T226M S2 5% 15mV positive Slower Slower [4],[9]
T226R S2 3% ? ? ? [10]
R239S S2 0% NA NA NA Improper trafficking [1],[3],[8]
A242P S2 10% 4mV Negative Slower Slower [11]
P244H S2-3 Unchanged Unchanged Unchanged Unchanged [11]
F249I S2-3 1% Unchanged Unchanged Slower Improper trafficking [1],[3],[4]
G311S S3-4 22.9% 30mV positive Unchanged Unchanged [8]
E325D S5 7.7% 52.4mV positive Faster Faster Impaired translation or stability [2],[3],[4],[12],[13],[14]
L329I S5 ? ? ? ? [15]
S342I S5 ? ? ? ? [16]
V404I S6 Unchanged 12mV positive Slower Slower [5],[11]
V408A C-terminus 68% Unchanged Faster Faster Shorter mean open time, more and larger sIPSCs in Mice [1],[3],[4],[7],[12],[13],[14],[17]
R417X C-terminus 2% 9mV positive Slower Faster Misfolds and form membranous aggregates [11],[18]
Current amplitude refers to the amount of current through mutant versus wild-type channels in cell culture or oocyte assays. Activation V½ is the potential at which the population of channels is half maximally activated which the accompanying τ is the time constant of the populations activation. Deactivation τ is similar to that of activation, referring instead to the time constant of population closing. sIPSCs are spontaneous inhibitory post synaptic currents. Cells with a red background indicate that this property will result in decreased KV1.1 current while cells with a green background indicate increased current through this channel.

EA2: CACNA1A

Figure 2. Schematic structure of CaV2.1 with the episodic ataxia type 2 mutations noted in red.

Type 2 episodic ataxia (EA2) is characterized by acetazolamide-responsive attacks of ataxia with or without migraine. Patients with EA2 may also present with progressive cerebellar atrophy, nystagmus, vertigo, visual disturbances and dysarthria. These symptoms last from hours to days, in contrast with EA1, which lasts from seconds to minutes. Like EA1, attacks can be precipitated by emotional or physical stress, but also by coffee and alcohol. EA2 is caused by mutations in CACNA1A, which encodes the P/Q-type voltage-gated calcium channel CaV2.1, and is also the gene responsible for causing spinocerebellar ataxia type-6 and familial hemiplegic migraine type-1. EA2 is also referred to as episodic ataxia with nystagmus, hereditary paroxysmal cerebellopathy, familial paroxysmal ataxia and acetazolamide-responsive hereditary paroxysmal cerebellar ataxia (AHPCA). There are currently 19 mutations associated with EA2, though only 3 have been characterized electrophysiologically, table 2 and figure 2. Of these, all result in decreased current through these channels. It is assumed that the other mutations, especially the splicing and frameshift mutations, also result in a drastic decrease in CaV2.1 currents, though this may not be the case for all mutations. CACNA1A is heavily expressed in Purkinje cells of the cerebellum where it is involved in coupling action potentials with neurotransmitter release. Thus, decrease in Ca2+ entry through CaV2.1 channels is expected to result in decreased output from Purkinje cells, even though they will fire at an appropriate rate. Alternatively, some CACNA1A mutations, such as those seen in familial hemiplegic migraine type-1, result in increased Ca2+ entry and, thereby, aberrant transmitter release. This can also result in excitotoxicity, as may occur in some cases of spinocerebellar ataxia type-6.

Table 2. Mutations in CACNA1A related to Episodic ataxia type-2
Mutation Position Effect Cerebellar Signs References
H253Y D1-pore ? Yes [19]
C271Y* D1-pore Decreased maximal current due to protein instability Yes [20]
G293R* D1-pore Decreased maximal current due to protein instability Yes [20],[21]
F624LfsX657 D2S5 ? Yes [19]
Q681RfsX780 D2-pore ? Yes [19]
S753fsX780 D2S6 ? Yes [22]
P1266LfsX1293 D3S1 ? Yes [22],[23]
R1278X D3S1-2 ? Yes [24]
F1391LfsX1429 D3S5 ? Yes [19]
Y1443X D3-pore ? Yes [22]
F1490K D3S6 No current, though expressed Yes [25]
R1546X D4S1 ? Yes [22]
A1593_Y1594delinsD D4S2 ? Yes [22]
R1661H D4S4 ? Yes [26]
R1664Q* D4S4 ? Yes [27]
E1756K D4-pore ? Yes [28]
Splicing Intron 11 ? Yes [22]
Splicing Intron 26 ? Yes [22]
Splicing Intron 28 ? Yes [23]
*
 Also diagnosed as Spinocerebellar ataxia type-6

EA3: 1q42

Episodic ataxia type-3 (EA3) is similar to EA1 but often also presents with tinnitus and vertigo. Patients typically present with bouts of ataxia lasting less than 30 minutes and occurring once or twice daily. During attacks, they also have vertigo, nausea, vomiting, tinnitus and diplopia. These attacks are sometimes accompanied by headaches and precipitated by stress, fatigue, movement and arousal after sleep. Attacks generally begin in early childhood and last throughout the patients' lifetime. Acetazolamide administration has proved successful in some patients.[29] As EA3 is extremely rare, there is currently no known causative gene. The locus for this disorder has been mapped to the q arm of chromosome 1 (1q42).[30]

EA4

Also known as periodic vestibulocerebellar ataxia, type-4 episodic ataxia (EA4) is an extremely rare form of episodic ataxia differentiated from other forms by onset in the third to sixth generation of life, defective smooth pursuit and gaze-evoked nystagmus. Patients also present with vertigo and ataxia. There are only two known families with EA4, both located in North Carolina. The locus for EA4 is unknown.

EA5: CACNB4

There are two known families with type-5 episodic ataxia (EA5). These patients can present with an overlapping phenotype of ataxia and seizures similar to juvenile myoclonic epilepsy. In fact, juvenile myoclonic epilepsy and EA5 are allelic and produce proteins with similar dysfunction. Patients with pure EA5 present with recurrent episodes of ataxia with vertigo. Between attacks the have nystagmus and dysarthria. These patients are responsive to acetazolamide. Both juvenile myoclonic epilepsy and EA5 are a result of mutations in CACNB4, a gene that encodes the calcium channel β4 subunit. This subunit coassembles with α-subunits and produces channels that slowly inactivate after opening. EA5 patients have a cysteine to phenylalanine mutation at position 104. Thus results in channels with 30% greater current than wild-type. As this subunit is expressed in the cerebellum, it is assumed that such increased current results in neuronal hyperexcitability.[31]

EA6: SLC1A3

Type-6 episodic ataxia (EA6) is a rare form of episodic ataxia, occurring in only one known patient. This patient, a 10 year-old boy at the time of clinical study, first presented with 30 minute bouts of decreased muscle tone during infancy. He required "balance therapy" as a young child to aid in walking and has a number of ataxic attacks, each separated by months to years. These attacks were precipitated by fever. He has cerebellar atrophy and subclinical seizures. During later attacks, he also presented with distortions of the left hemifield, ataxia, slurred speech, followed by headache. After enrolling in school, he developed bouts of rhythmic arm jerking with concomitant confusion, also lasting approximately 30 minutes. He also has presented, at various times, with migraines. This patient carries a proline to arginine substitution in the fifth transmembrane-spanning segment of the gene SLC1A3. This gene encodes the excitatory amino acid transporter 1 (EAAT1) protein, which is responsible for glutamate uptake. In cell culture assays, this mutation results in drastically decreased glutamate uptake in a dominant-negative manner. This is likely due to decreased synthesis or protein stability. As this protein is expressed heavily in the brainstem and cerebellum, it is likely that this mutation results in excitotoxicity and/or hyperexcitability leading to ataxia and seizures.[32]

Treatment

Depending on subtype, many patients find that acetazolamide therapy is useful in preventing attacks. In some cases, persistent attacks result in tendon shortening, for which surgery is required.

External links

Footnotes

  1. ↑ 1.0 1.1 1.2 1.3 Browne D, Gancher S, Nutt J, Brunt E, Smith E, Kramer P, Litt M (1994). "Episodic ataxia/myokymia syndrome is associated with point mutations in the human potassium channel gene, KCNA1". Nat Genet. 8 (2): 136–40. PMID 7842011.
  2. ↑ 2.0 2.1 2.2 Browne D, Brunt E, Griggs R, Nutt J, Gancher S, Smith E, Litt M (1995). "Identification of two new KCNA1 mutations in episodic ataxia/myokymia families". Hum Mol Genet. 4 (9): 1671–2. PMID 8541859.
  3. ↑ 3.0 3.1 3.2 3.3 3.4 3.5 Adelman J, Bond C, Pessia M, Maylie J (1995). "Episodic ataxia results from voltage-dependent potassium channels with altered functions". Neuron. 15 (6): 1449–54. PMID 8845167.
  4. ↑ 4.0 4.1 4.2 4.3 4.4 4.5 Zerr P, Adelman J, Maylie J (1998). "Episodic ataxia mutations in Kv1.1 alter potassium channel function by dominant negative effects or haploinsufficiency". J Neurosci. 18 (8): 2842–8. PMID 9526001.
  5. ↑ 5.0 5.1 5.2 Scheffer H, Brunt E, Mol G, van der Vlies P, Stulp R, Verlind E, Mantel G, Averyanov Y, Hofstra R, Buys C (1998). "Three novel KCNA1 mutations in episodic ataxia type I families". Hum Genet. 102 (4): 464–6. PMID 9600245.
  6. ↑ Imbrici P, Cusimano A, D'Adamo M, De Curtis A, Pessia M (2003). "Functional characterization of an episodic ataxia type-1 mutation occurring in the S1 segment of hKv1.1 channels". Pflugers Arch. 446 (3): 373–9. PMID 12799903.
  7. ↑ 7.0 7.1 Bretschneider F, Wrisch A, Lehmann-Horn F, Grissmer S (1999). "Expression in mammalian cells and electrophysiological characterization of two mutant Kv1.1 channels causing episodic ataxia type 1 (EA-1)". Eur J Neurosci. 11 (7): 2403–12. PMID 10383630.
  8. ↑ 8.0 8.1 8.2 Zerr P, Adelman J, Maylie J (1998). "Characterization of three episodic ataxia mutations in the human Kv1.1 potassium channel". FEBS Lett. 431 (3): 461–4. PMID 9714564.
  9. ↑ Comu S, Giuliani M, Narayanan V (1996). "Episodic ataxia and myokymia syndrome: a new mutation of potassium channel gene Kv1.1". Ann Neurol. 40 (4): 684–7. PMID 8871592.
  10. ↑ Zuberi S, Eunson L, Spauschus A, De Silva R, Tolmie J, Wood N, McWilliam R, Stephenson J, Kullmann D, Hanna M (1999). "A novel mutation in the human voltage-gated potassium channel gene (Kv1.1) associates with episodic ataxia type 1 and sometimes with partial epilepsy". Brain. 122 ( Pt 5): 817–25. PMID 10355668.
  11. ↑ 11.0 11.1 11.2 11.3 Eunson L, Rea R, Zuberi S, Youroukos S, Panayiotopoulos C, Liguori R, Avoni P, McWilliam R, Stephenson J, Hanna M, Kullmann D, Spauschus A (2000). "Clinical, genetic, and expression studies of mutations in the potassium channel gene KCNA1 reveal new phenotypic variability". Ann Neurol. 48 (4): 647–56. PMID 11026449.
  12. ↑ 12.0 12.1 D'Adamo M, Liu Z, Adelman J, Maylie J, Pessia M (1998). "Episodic ataxia type-1 mutations in the hKv1.1 cytoplasmic pore region alter the gating properties of the channel". EMBO J. 17 (5): 1200–7. PMID 9482717.
  13. ↑ 13.0 13.1 D'Adamo M, Imbrici P, Sponcichetti F, Pessia M (1999). "Mutations in the KCNA1 gene associated with episodic ataxia type-1 syndrome impair heteromeric voltage-gated K(+) channel function". FASEB J. 13 (11): 1335–45. PMID 10428758.
  14. ↑ 14.0 14.1 Maylie B, Bissonnette E, Virk M, Adelman J, Maylie J (2002). "Episodic ataxia type 1 mutations in the human Kv1.1 potassium channel alter hKvbeta 1-induced N-type inactivation". J Neurosci. 22 (12): 4786–93. PMID 12077175.
  15. ↑ Knight M, Storey E, McKinlay Gardner R, Hand P, Forrest S (2000). "Identification of a novel missense mutation L329I in the episodic ataxia type 1 gene KCNA1--a challenging problem". Hum Mutat. 16 (4): 374. PMID 11013453.
  16. ↑ Lee H, Wang H, Jen J, Sabatti C, Baloh R, Nelson S (2004). "A novel mutation in KCNA1 causes episodic ataxia without myokymia". Hum Mutat. 24 (6): 536. PMID 15532032.
  17. ↑ Herson P, Virk M, Rustay N, Bond C, Crabbe J, Adelman J, Maylie J (2003). "A mouse model of episodic ataxia type-1". Nat Neurosci. 6 (4): 378–83. PMID 12612586.
  18. ↑ Manganas L, Akhtar S, Antonucci D, Campomanes C, Dolly J, Trimmer J (2001). "Episodic ataxia type-1 mutations in the Kv1.1 potassium channel display distinct folding and intracellular trafficking properties". J Biol Chem. 276 (52): 49427–34. PMID 11679591.
  19. ↑ 19.0 19.1 19.2 19.3 van den Maagdenberg A, Kors E, Brunt E, van Paesschen W, Pascual J, Ravine D, Keeling S, Vanmolkot K, Vermeulen F, Terwindt G, Haan J, Frants R, Ferrari M (2002). "Episodic ataxia type 2. Three novel truncating mutations and one novel missense mutation in the CACNA1A gene". J Neurol. 249 (11): 1515–9. PMID 12420090.
  20. ↑ 20.0 20.1 Wan J, Khanna R, Sandusky M, Papazian D, Jen J, Baloh R (2005). "CACNA1A mutations causing episodic and progressive ataxia alter channel trafficking and kinetics". Neurology. 64 (12): 2090–7. PMID 15985579.
  21. ↑ Yue Q, Jen J, Nelson S, Baloh R (1997). "Progressive ataxia due to a missense mutation in a calcium-channel gene". Am J Hum Genet. 61 (5): 1078–87. PMID 9345107.
  22. ↑ 22.0 22.1 22.2 22.3 22.4 22.5 22.6 Denier C, Ducros A, Vahedi K, Joutel A, Thierry P, Ritz A, Castelnovo G, Deonna T, Gérard P, Devoize J, Gayou A, Perrouty B, Soisson T, Autret A, Warter J, Vighetto A, Van Bogaert P, Alamowitch S, Roullet E, Tournier-Lasserve E (1999). "High prevalence of CACNA1A truncations and broader clinical spectrum in episodic ataxia type 2". Neurology. 52 (9): 1816–21. PMID 10371528.
  23. ↑ 23.0 23.1 Ophoff R, Terwindt G, Vergouwe M, van Eijk R, Oefner P, Hoffman S, Lamerdin J, Mohrenweiser H, Bulman D, Ferrari M, Haan J, Lindhout D, van Ommen G, Hofker M, Ferrari M, Frants R (1996). "Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4". Cell. 87 (3): 543–52. PMID 8898206.
  24. ↑ Yue Q, Jen J, Thwe M, Nelson S, Baloh R (1998). "De novo mutation in CACNA1A caused acetazolamide-responsive episodic ataxia". Am J Med Genet. 77 (4): 298–301. PMID 9600739.
  25. ↑ Guida S, Trettel F, Pagnutti S, Mantuano E, Tottene A, Veneziano L, Fellin T, Spadaro M, Stauderman K, Williams M, Volsen S, Ophoff R, Frants R, Jodice C, Frontali M, Pietrobon D (2001). "Complete loss of P/Q calcium channel activity caused by a CACNA1A missense mutation carried by patients with episodic ataxia type 2". Am J Hum Genet. 68 (3): 759–64. PMID 11179022.
  26. ↑ Friend K, Crimmins D, Phan T, Sue C, Colley A, Fung V, Morris J, Sutherland G, Richards R (1999). "Detection of a novel missense mutation and second recurrent mutation in the CACNA1A gene in individuals with EA-2 and FHM". Hum Genet. 105 (3): 261–5. PMID 10987655.
  27. ↑ Tonelli A, D'Angelo M, Salati R, Villa L, Germinasi C, Frattini T, Meola G, Turconi A, Bresolin N, Bassi M (2006). "Early onset, non fluctuating spinocerebellar ataxia and a novel missense mutation in CACNA1A gene". J Neurol Sci. 241 (1–2): 13–7. PMID 16325861.
  28. ↑ Denier C, Ducros A, Durr A, Eymard B, Chassande B, Tournier-Lasserve E (2001). "Missense CACNA1A mutation causing episodic ataxia type 2". Arch Neurol. 58 (2): 292–5. PMID 11176968.
  29. ↑ Steckley J, Ebers G, Cader M, McLachlan R (2001). "An autosomal dominant disorder with episodic ataxia, vertigo, and tinnitus". Neurology. 57 (8): 1499–502. PMID 11673600.
  30. ↑ Cader M, Steckley J, Dyment D, McLachlan R, Ebers G (2005). "A genome-wide screen and linkage mapping for a large pedigree with episodic ataxia". Neurology. 65 (1): 156–8. PMID 16009908.
  31. ↑ Escayg A, De Waard M, Lee D, Bichet D, Wolf P, Mayer T, Johnston J, Baloh R, Sander T, Meisler M (2000). "Coding and noncoding variation of the human calcium-channel beta4-subunit gene CACNB4 in patients with idiopathic generalized epilepsy and episodic ataxia". Am J Hum Genet. 66 (5): 1531–9. PMID 10762541.
  32. ↑ Jen J, Wan J, Palos T, Howard B, Baloh R (2005). "Mutation in the glutamate transporter EAAT1 causes episodic ataxia, hemiplegia, and seizures". Neurology. 65 (4): 529–34. PMID 16116111.

Template:WH Template:WS

Retrieved from "https://www.wikidoc.org/index.php?title=Episodic_ataxia&oldid=1194891"